Gensight Biologics S.A.
- BID
0.079
- ASK
0.085
- 126,582 Units117,647 Units
- 07/21, 21:57:11 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
36.79%
Market Cap
30.38 Mil.
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.08 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 0.079 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 09:57:11 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 0.0819 | 0.0748 |
| PREV. DAY'S PRICE | 0.078 | (07/20) |
| CHANGE DAY BEFORE | +0.00 | 1.28 % |
| 52 WEEK HIGH / LOW | 0.183 (10/30) | 0.0594 (06/15) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.54 | -0.15 | -0.08 | -0.20 | -0.81 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | - | - | - | - | - |
PRICE - SALES RATIO | 17.54 | 17.24 | 15,486.45 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A2ANGZ |
| ISIN | FR0013183985 |
| SYMBOL | G49N |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | GENSIGHT BIOLOG. EO -,025 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Euro |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 78.11 Mil. |
| MARKET CAPITALISATION | 30.38 Mil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -1.27 % | -5.45 % | -2.50 % | -7.36 % | -36.79 % | -88.84 % | -99.03 % | -31.22 % |
| HIGH | 0.08 | 0.09 | 0.09 | 0.12 | 0.18 | 0.83 | 8.51 | 0.12 |
| LOW | 0.07 | 0.07 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 |
Dividende
pro Aktie
GENSIGHT BIOLOG. EO -,025 does not deliver dividend information
Company profile
GenSight Biologics SA is a clinical-stage gene therapy company, which engages in research and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye. It also focuses on central nervous system diseases. The company was founded by Bernard Jacques Alex Gilly, Botond Roska, Jean Bennett, Connie Cepko, Luk H. Vandenberghe, Serge Picaud and Jose-Alain Sahel in 2012 and is headquartered in Paris, France.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.